Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of pharmacogenetic markers in smoking cessation therapy.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics - 5 Sept 2008

Heitjan Daniel F, Guo Mengye, Ray Riju, Wileyto E Paul, Epstein Leonard H, Lerman Caryn

Abstract excerpt

Pharmacogenetic clinical trials seek to identify genetic modifiers of treatment effects. When a trial has collected data on many potential genetic markers, a first step in analysis is to screen for evidence of pharmacogenetic effects by testing for treatment-by-marker interactions in a statistical model for the outcome of interest. This approach is potentially problematic because (i) individual significance tests...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Second-Generation
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bupropion

Share to Choline O-Acetyltransferase

Share to Placebos

Share to Receptors, Nicotinic

Share to Smoking Cessation

Share to Tobacco Use Disorder

Source

Open in PubMed Open full text

Identifiers

PMID: 18165968
DOI: 10.1002/ajmg.b.30669
PMCID: PMC2655206

Genes

CHRNA5
CHAT
CHRNA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of pharmacogenetic markers in smoking cessation therapy.PMID 18165968Read ↗

The Role of Pharmacogenetics in Smoking.Semantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings.Semantic proximity Read ↗

A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation.Semantic proximity Read ↗

Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy.Semantic proximity Read ↗

From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.Semantic proximity Read ↗

Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.Semantic proximity Read ↗

Pharmacogenetics and nicotine addiction treatment.Semantic proximity Read ↗

Molecular genetics of successful smoking cessation: convergent genome-wide association study results.Semantic proximity Read ↗

Smoking cessation treatment: pharmacogenetic assessment.Semantic proximity Read ↗

Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.